[Frontiers in Bioscience 1, a46-58, August 16, 1996]


Jonathan S. Wall1, Fayad M. Ayoub2, and Paul S. O'Shea

1 Human Immunology & Cancer Program, University of Tennessee Medical Center at Knoxville, 1924 Alcoa Highway, Knoxville, TN 37920-6999. USA.

2 Department of Biological & Chemical Sciences, University of Essex, Colchester, Essex, England U.K.

Received 01/11/96; Accepted 05/29/96; On-line 08/16/96


1. Barlogie, B., Epstein, J., Selvanayagam, P. and Alexanian, R. Plasma cell myeloma- new biological insights and advances in therapy. Blood, 73, No. 4, 865-879 (1989)

2. Katzin, W.E. Cancer (multiple myeloma and related disorders). Clin Chem, 65, No. 12, 382R-387R (1993)

3. Solomon, A. Clinical implications of monoclonal light chains Sem Oncol, 13, No. 3, 341-349 (1986)

4. Prado, M.J.B.A, Nicastri, A.L., Leo, P., Uchino, E., Sesso, A., Marcondes, M. and Prado, E.B.A. Nephrotoxicity of human Bence Jones proteins in rats: proteinuria and enzyuria profile. Brazilian J. Med Biol Res, 26, 633-638 (1993)

5. Buxbaum, J.N., Chuba, J.V., Hellman, G.C., Solomon, A. and Gallo, G.R. Monoclonal immunoglobulin deposition disease: Light chain and heavy chain deposition diseases and their relation to light chain amyloidosis. Ann Int Med 112, No. 6, 455-464 (1990)

6. Solomon, A, Weiss, D.T. and Williams, T.K. Experimental model of human light-chain-associated disease. Curr Top Microbiol Immunol, 182, 261-267 (1992)

7. Huang, Z-Q., Kirk, K.A., Connelly, K.G. and Sanders, P.W. Bence jones proteins bind to a common peptide segment of Tamm-Horsfall glycoprotein to promote heterotypic aggregation. J Clin Inv, 92, 2975-2983 (1993)

8. Somer, T. The viscosity of blood, plasma and serum in dys- and paraproteinemias. Acta Med Scand. Suppl, (456), 180, 1-97 (1966)

9. Jacobson, D.R. and Zolla-Pazner, S. Immuno-suppression and infection in multiple myeloma. Sem Oncol, 13, (3), 282-290 (1992)

10. Winkelstein, A. and Jordan, S. Immune deficiencies in chronic lymphocytic leukemia and multiple myeloma. Clin Rev Allergy, 10, (1-2), 39-58 (1992)

11. Mei, S., Mody, B., Eklund, S.H. and Paul, S. Vasoactive intestinal peptide, hydrolysis by antibody light chains. J Biol Chem, 266, 15571-15574 (1991)

12. Erhan, S. and Geller, L.D. Do immunoglobulins have proteolytic activity? Nature, 251, 353-355 (1974)

13. Meri, S., Koistinen, V., Miettinen, A., Törnroth, T. and Seppälä, J.T. Activation of the alternative pathway of complement by monoclonal lambda light chains in membranoproliferative glomerulonephritis. J Exp Med, 175, 939-950 (1992)

14. Edmundson, A.B. and Ely, K.R. Binding of N-formylated chemotactic peptides in crystals of the Mcg light chain dimer: Similarities with neutrophil receptors. Mol Immunol, 22, (4), 463-475 (1985)

15. Edmundson, A.B., Ely, K.R., Herron, J.M. and Cheson, B.D. The binding of opioid peptides to the Mcg light chain dimer: Flexible keys and adjustable locks. Mol Immunol, 24, (9), 915-935 (1987)

16. Mei, S., Lan, L., Qing Sheng, G. and Sudhir, P. Antigen recognition by an antibody light chain. J Biol Chem, 269, No.1, 734-738 (1994)

17. Masat, L., Wabl, M. and Johnson, J.P. A simpler sort of antibody. Proc Natl Acad Sci., 91, 893-896 (1994)

18. Mahana, W., Jacquemart, F. and Ermonval, M. A murine monoclonal multureactive immunolgobulin kappa light chain. Scand J Immunol, 39, 107-110 (1994)

19. Ludwig, L. B., Schwartz, S.A. and Insel, R.A. Human monoclonal lambda light chain protein exhibits specific binding to the variable region of monoclonal anti-IgE antibody. Cell Immunol 153, 117-130 (1994)

20. Schiffer, G., Girling, R.L., Ely, K.R. and Edmundson, A.B. Structure of lambda-type Bence-Jones protein at 3.5-Å resolution. Biochem, 12, 4620-4631 (1973)

21. Wearne, A.J., Joshua, D.E. and Kronengerg, H. Light chain isotype associated suppression of surface immunoglobulin expression on peripheral blood lymphocytes in myeloma during plateau phase. British J Haematol, 58, 483-489 (1984a)

22. Wearne, A.J., Joshua, D.E., Young, G.A.R. and Kronengerg, H. Multiple myeloma: Light chain isotype suppression- A marker of stable disease at presentation. Eur J Haematol, 38, 43-49 (1984b)

23. Ioannidis, R.A., Joshua, D.E., Warburton, P.T., Francis, S.E., Brown, R.D., Gibson, J. and Kronengerg, H. Multiple myeloma: Evidence that light chains play an immunoregulatory role in B-cell regulation. Hemat Path, 3, (4), 169-175 (1989)

24. Joshua, D.E., Ioannidis, R.A., Brown, R.D., Francis, S.E., Gibson, J. and Kronengerg, H. Multiple myeloma: Relationship between light chain isotype suppression, labelling index of plasma cells, and CD38 expression on peripheral blood lymphocytes. Am J Hemat, 29, 5-11 (1988)

25. King, M.A. and Raddichi, M.A. Monitoring circulating B cells in patients with multiple myeloma at diagnosis or in plateau phase: How prevalent is light chain isotype suppression? Brit J Haemat, 81, 281-222 (1992)

26. Tenser, R.B., Hay, K.A. and Aberg, J.A Immunoglobulin G immunosuppression of multiple sclerosis. Archives in Neurology, 50, 417-420. (1993)

27. Ling, Z-D, Yeoh, E., Webb, B.T., Farrell, K., Doucette, J. and Matheson, D.S. Intravenous immunoglobulin induces interferon-gamma and interleukin-6 in vivo. J. Clin Immunol, 13, (5), 202- 309 (1993)

28. Portier, M., Zhang, X-G., Caron, E., Lu, Z-Y., Bataille, R. and Klien, B. gamma-interferon in multiple myeloma: Inhibition of interleukin-6 (IL-6)-dependent myeloma cell growth and down regulation of IL-6-receptor expression in vitro. Blood, 8, (11), 3076-3082 (1993).

29. Lasfar, A., Wietzerbin,, J. and Billard, C. Differential regulation of interleukin-6 receptors by interleukin-6 and interferons in multiple myeloma cell lines. Eur J Immunol, 24, 124-130 (1994)

30. Grawunder, U., Melchers, F. and Rolink, A. Interferon-gamma arrests proliferation and causes apoptosis in stromal cell/interleukin-7-dependent normal murine pre-B cell lines and clones in vitro, but does not induce differentiation to surface immunoglobulin-positive B cells. Eur J Immunol, 23, 544-551 (1993)

31. Batuman, V., Dreisbach, A.W. and Cyran, J. Light-chain binding sites on renal brush-border membranes. Am J Physiol, 258, F1259-F1265 (1990)

32. Dreisbach, A.W. and Batuman, V. Low-molecular-weight protein competition for binding sites on renal brush border membranes. Renal Physiol, 17, 287-293 (1994)

33. Wochner, R.D., Strober, W. and Waldmann, T.A. The role of the kidney in the catabolism of Bence jones proteins and immunoglobulin fragments. J Exp Med, 126, 207 (1967)

34. Wall, J.S., Golding, C., van Veen, M. and O'Shea, P.S. The use of fluoresceinphosphatidylethanolamine as a real-time probe for peptide-membrane interactions. Mol Memb Biol, 12, (2), 181-190 (1995a)

35. Wall, J.S., Ayoub, F. M. & O'Shea, P.S. Interactions of macromolecules with the mammalian cell surface. J Cell Science, 108, 2673-2682 (1995b)

36. Wall, J.S., Ayoub, F. M. & O'Shea, P.S. Studies of the interaction of bovine serum albumin with phospholipid vesicles. Manuscript in preparation. (1995c)

37. Bergers, J.J., Vingerhoeds, M.H., van Bloois, L., Herron, J.N., Janssen, L.H.M., Fischer, M.J.E. and Crommelin, D.J.A. The role of protein charge in protein-lipid interactions. pH-dependent changes of the electrophoretic mobility of liposomes through adsorption of water-soluble, globular proteins. Biochem, 32, 4641-4649 (1993)

38. McLaughlin. S. Electrostatic potentials at membrane-solution interfaces. Curr Top Membr Trans, 9, 71-144 (1977)

39. McLaughlin. S. The electrostatic properties of membranes. Ann Rev Biophys Biophys Chem, 18, 113-136 (1989)

40. Cevc, G. Membrane electrostatics. Biochimica Biophysica Acta, 1031-3, 311-382 (1990)

41. Lichtenberg, D. and Barenholz, Y. Liposomes: preparation, characterisation and preservation. Methods of Biochemical Analysis, 33, 337-462 (1988)

42. Hope, M.J. Nayar, R., Mayer, L.D. and Cullis, P.R. Reduction of liposome size and preparation of unilamellar vesicles by extrusion techniques. In Liposome Technology-Volume 1, (Edited by Gregoriadis G.) p. 123-139, CRC Press (1993)

43. MacDonald, R.C. and MacDonald, R. I. Applications of freezeing and thawing in liposome technology. In Liposome Technology-Volume 1, (Edited by Gregoriadis G.) p. 209-228, CRC Press Boca Raton. Fl. USA (1993)

44. Hobbs, J.R. Bence-Jones proteins. Essays Med Biochem, 1, 105-131 (1975)

45. Whicher, J.T., Calvin, J., Riches, P. and Warren, C. The laboratory investigation of paraproteinaemia. Ann Clin Biochem, 24, 119-132 (1987)

46. Whittaker, J.R., and Granum, P. E., An absolute method for protein determination based on differences of absorbance at 235 and 280nm. Analytical Biochemistry, 109, 156 (1980)

47. Moore, W.J. Physical chemistry, 5th edition. Prentice-Hall Inc, New Jersey (1974)

48. McLaughlin, S., Bruder, A., Chen, S. and Moser, C. Chaotropic anions and the surface potential of bilayer membranes. Biochimica Biophysica Acta, 394, 304-313 (1975)

49. Hatefi, Y. and Hanstein, W.G. Solubilization of particulate proteins and nonelectrolytes by chaotropic agents. Proc Natl Acad Sci, 62, 1129-1136 (1969)

50. Campbell, I.D. and Dwek, R.A. Biological spectroscopy, Bejamin/Cummings, California (1984)

51. Norden, A.G.W., Flynn, F.V., Fulcher, L.M. and Richrads, J.D.M. Renal impairment in myeloma: negative association with isoelectric point of excreted Bence-Jones protein. J Clin Pathol, 42, 59-62 (1989)

[Table of Contents ] [Previous Section]